Panbela announces pricing of approximately $9.0 million public offering

Minneapolis, jan. 29, 2024 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “common warrants”) at a purchase price of $2.06 per share and associated common warrants. the common warrants will have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. the common warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events. the offering is expected to close on or about january 31, 2024, subject to customary closing conditions.
PBLA Ratings Summary
PBLA Quant Ranking